Table 6 Virally-induced cancers subject to control by vaccines.
From: Progress and controversies in developing cancer vaccines
Cancer histology | Etiologic virus | Vaccine strategy | Current use | Clinical value |
|---|---|---|---|---|
Hepatoma | Hepatitis B | Protein subunit vaccine | In common use for high-risk populations. | Protection against Hepatitis B infection is prolonged after three vaccines. Worldwide protection against hepatoma may have dramatic impact. |
Cervical adenocarcinoma | Human Papilloma Virus | Viral and other vaccines against E6 and E7 | Strong evidence for efficacy in certain populations | Likely will protect against cancer, especially for patients without access to Pap smears |
Burkitt's lymphoma, Nasopharyngeal cancer | Epstein-Barr Virus | Some T cell antigens identified | Vaccines would have to be administered very early in life | Untested. |